Akut solunum sıkıntısı sendromu (ARDS) ve onun daha az ciddi formu olan akut akciğer hasarı (AAH) 1960'lı yıllardan beri değişik isim ve tanımlar altında bilinmektedir. Sendromun etyopatogenezi geniş şekilde araştırılmıştır, ancak tıptaki gelişmelere rağmen tedavi seçenekleri ve prognozun hala iyileştirilmeye ihtiyacı vardır. Tedavi girişimlerinin temelini mekanik ventilasyon oluşturmakta olup, yeni modlar ve ventilasyon stratejileri umut vaad etmektedir. Maalesef mevcut farmakolojik ajanların hiçbirinin mortaliteyi azalttığı gösterilmemiştir. Ancak bazı belirli hasta altgruplarıyla yapılan çalışmalar kişiselleştirilmiş tedavi seçeneklerinin genelleyici yaklaşıma göre daha iyi sonuçlar ortaya koyacağını göstermektedir.
Acute respiratory distress syndrome (ARDS) and its less serious form acute lung injury (ALI) have been recognized since 1960s under different names and descriptions. The etiopathogenesis of the syndrome has been studied widely but despite of developments in medicine, treatment choices and the prognosis still need to be improved. Mechanical ventilation is the mainstay of therapeutic interventions and new modes and ventilation strategies seem promising. Unfortunately none of the pharmacological agents available is shown to reduce mortality. However, studies concerning with some certain subgroups of patients show that individualized treatment options, rather than general approach, will result in better outcome. "> [PDF] Akut solunum sıkıntısı sendromu | [PDF] Acute respiratory distress syndrome Akut solunum sıkıntısı sendromu (ARDS) ve onun daha az ciddi formu olan akut akciğer hasarı (AAH) 1960'lı yıllardan beri değişik isim ve tanımlar altında bilinmektedir. Sendromun etyopatogenezi geniş şekilde araştırılmıştır, ancak tıptaki gelişmelere rağmen tedavi seçenekleri ve prognozun hala iyileştirilmeye ihtiyacı vardır. Tedavi girişimlerinin temelini mekanik ventilasyon oluşturmakta olup, yeni modlar ve ventilasyon stratejileri umut vaad etmektedir. Maalesef mevcut farmakolojik ajanların hiçbirinin mortaliteyi azalttığı gösterilmemiştir. Ancak bazı belirli hasta altgruplarıyla yapılan çalışmalar kişiselleştirilmiş tedavi seçeneklerinin genelleyici yaklaşıma göre daha iyi sonuçlar ortaya koyacağını göstermektedir. "> Akut solunum sıkıntısı sendromu (ARDS) ve onun daha az ciddi formu olan akut akciğer hasarı (AAH) 1960'lı yıllardan beri değişik isim ve tanımlar altında bilinmektedir. Sendromun etyopatogenezi geniş şekilde araştırılmıştır, ancak tıptaki gelişmelere rağmen tedavi seçenekleri ve prognozun hala iyileştirilmeye ihtiyacı vardır. Tedavi girişimlerinin temelini mekanik ventilasyon oluşturmakta olup, yeni modlar ve ventilasyon stratejileri umut vaad etmektedir. Maalesef mevcut farmakolojik ajanların hiçbirinin mortaliteyi azalttığı gösterilmemiştir. Ancak bazı belirli hasta altgruplarıyla yapılan çalışmalar kişiselleştirilmiş tedavi seçeneklerinin genelleyici yaklaşıma göre daha iyi sonuçlar ortaya koyacağını göstermektedir.
Acute respiratory distress syndrome (ARDS) and its less serious form acute lung injury (ALI) have been recognized since 1960s under different names and descriptions. The etiopathogenesis of the syndrome has been studied widely but despite of developments in medicine, treatment choices and the prognosis still need to be improved. Mechanical ventilation is the mainstay of therapeutic interventions and new modes and ventilation strategies seem promising. Unfortunately none of the pharmacological agents available is shown to reduce mortality. However, studies concerning with some certain subgroups of patients show that individualized treatment options, rather than general approach, will result in better outcome. ">

Akut solunum sıkıntısı sendromu

Akut solunum sıkıntısı sendromu (ARDS) ve onun daha az ciddi formu olan akut akciğer hasarı (AAH) 1960'lı yıllardan beri değişik isim ve tanımlar altında bilinmektedir. Sendromun etyopatogenezi geniş şekilde araştırılmıştır, ancak tıptaki gelişmelere rağmen tedavi seçenekleri ve prognozun hala iyileştirilmeye ihtiyacı vardır. Tedavi girişimlerinin temelini mekanik ventilasyon oluşturmakta olup, yeni modlar ve ventilasyon stratejileri umut vaad etmektedir. Maalesef mevcut farmakolojik ajanların hiçbirinin mortaliteyi azalttığı gösterilmemiştir. Ancak bazı belirli hasta altgruplarıyla yapılan çalışmalar kişiselleştirilmiş tedavi seçeneklerinin genelleyici yaklaşıma göre daha iyi sonuçlar ortaya koyacağını göstermektedir.

Acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) and its less serious form acute lung injury (ALI) have been recognized since 1960s under different names and descriptions. The etiopathogenesis of the syndrome has been studied widely but despite of developments in medicine, treatment choices and the prognosis still need to be improved. Mechanical ventilation is the mainstay of therapeutic interventions and new modes and ventilation strategies seem promising. Unfortunately none of the pharmacological agents available is shown to reduce mortality. However, studies concerning with some certain subgroups of patients show that individualized treatment options, rather than general approach, will result in better outcome.

___

  • 1) Frutos-Vivar F, Nin N, Esteban A. Epidemiology of acute lung injury and acute respiratory distress syndrome. Curr Opin Crit Care 2004;10:1-6.
  • 2) Zaccardelli DS, Pattishall EN. Clinical diagnostic criteria of the adult respiratory distress syndrome in the intensive care unit. Crit Care Med 1996;24:247-51.
  • 3) Esteban A, Anzueto A, Frutos F, Alía I, Brochard L, Stewart TE, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002;287:345-55.
  • 4) Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, et al. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med 1999;159:1849-61.
  • 5) Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-93.
  • 6) Iribarren C, Jacobs DR Jr, Sidney S, Gross MD, Eisner MD. Cigarette smoking, alcohol consumption, and risk of ARDS: a 15-year cohort study in a managed care setting. Chest 2000;117:163-8.
  • 7) Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, et al. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;157:1332-47.
  • 8) Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB, et al. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007;132:410-7.
  • 9) Joynt GM, Antonio GE, Lam P, Wong KT, Li T, Gomersall CD, et al. Late-stage adult respiratory distress syndrome caused by severe acute respiratory syndrome: abnormal findings at thin-section CT. Radiology 2004;230:339-46.
  • 10) Desai SR. Acute respiratory distress syndrome: imaging of the injured lung. Clin Radiol 2002;57:8-17.
  • 11) Ichikado K, Johkoh T, Ikezoe J, Takeuchi N, Kohno N, Arisawa J, et al. Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. AJR Am J Roentgenol 1997;168:333-8.
  • 12) Ichikado K, Suga M, Muranaka H, Gushima Y, Miyakawa H, Tsubamoto M, et al. Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. Radiology 2006;238:321-9.
  • 13) Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;151:293-301.
  • 14) Fowler AA, Hamman RF, Good JT, Benson KN, Baird M, Eberle DJ, et al. Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med 1983;98:593-7.
  • 15) Kuriyan M, Carson JL. Blood transfusion risks in the intensive care unit. Crit Care Clin 2004;20:237-53.
  • 16) Tietjen PA, Kaner RJ, Quinn CE. Aspiration emergencies. Clin Chest Med 1994;15:117-35.
  • 17) Wynne JW. Aspiration pneumonitis. Correlation of experimental models with clinical disease. Clin Chest Med 1982; 3:25-34.
  • 18) Park BJ. Respiratory failure following pulmonary resection. Semin Thorac Cardiovasc Surg 2007;19:374-9.
  • 19) Kutlu CA, Williams EA, Evans TW, Pastorino U, Goldstraw P. Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 2000;69:376-80.
  • 20) Alam N, Park BJ, Wilton A, Seshan VE, Bains MS, Downey RJ, et al. Incidence and risk factors for lung injury after lung cancer resection. Ann Thorac Surg 2007;84:1085-91.
  • 21) Frank JA, Nuckton TJ, Matthay MA. Diabetes mellitus: a negative predictor for the development of acute respiratory distress syndrome from septic shock. Crit Care Med 2000;28:2645-6.
  • 22) Calandrino FS Jr, Anderson DJ, Mintun MA, Schuster DP. Pulmonary vascular permeability during the adult respiratory distress syndrome: a positron emission tomographic study. Am Rev Respir Dis 1988;138:421-8.
  • 23) Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;163:1376-83.
  • 24) Melot C, Naeije R, Mols P, Hallemans R, Lejeune P, Jaspar N. Pulmonary vascular tone improves pulmonary gas exchange in the adult respiratory distress syndrome. Am Rev Respir Dis 1987;136:1232-6.
  • 25) Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
  • 26) Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005;33:1-6.
  • 27) Chollet-Martin S, Gatecel C, Kermarrec N, Gougerot- Pocidalo MA, Payen DM. Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 1996;153:985-90.
  • 28) Piantadosi CA, Schwartz DA. The acute respiratory distress syndrome. Ann Intern Med 2004;141:460-70.
  • 29) Windsor AC, Mullen PG, Fowler AA, Sugerman HJ. Role of the neutrophil in adult respiratory distress syndrome. Br J Surg 1993;80:10-7.
  • 30) Gadek JE, Pacht ER. The interdependence of lung antioxidants and antiprotease defense in ARDS. Chest 1996;110(6 Suppl):273S-277S.
  • 31) Donnelly SC, MacGregor I, Zamani A, Gordon MW, Robertson CE, Steedman DJ, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med 1995;151:1428-33.
  • 32) Matute-Bello G, Liles WC, Radella F 2nd, Steinberg KP, Ruzinski JT, Hudson LD, et al. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med 2000;28:1-7.
  • 33) Bowler RP, Duda B, Chan ED, Enghild JJ, Ware LB, Matthay MA, et al. Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004;286:L1095-104.
  • 34) Tomashefski JF Jr. Pulmonary pathology of the adult respiratory distress syndrome. Clin Chest Med 1990;11:593-619.
  • 35) Gattinoni L, Bombino M, Pelosi P, Lissoni A, Pesenti A, Fumagalli R, et al. Lung structure and function in different stages of severe adult respiratory distress syndrome. JAMA 1994;271:1772-9.
  • 36) Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995;273:306-9.
  • 37) Ely EW, Wheeler AP, Thompson BT, Ancukiewicz M, Steinberg KP, Bernard GR. Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome. Ann Intern Med 2002;136:25-36.
  • 38) Monchi M, Bellenfant F, Cariou A, Joly LM, Thebert D, Laurent I, et al. Early predictive factors of survival in the acute respiratory distress syndrome. A multivariate analysis. Am J Respir Crit Care Med 1998;158:1076-81.
  • 39) Estenssoro E, Dubin A, Laffaire E, Canales H, Sáenz G, Moseinco M, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med 2002;30:2450-6.
  • 40) Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 1998;157:1159-64.
  • 41) Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, et al. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med 2009;179:220-7.
  • 42) Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 2006;21:119-43.
  • 43) Gattinoni L, Pelosi P, Suter PM, Pedoto A, Vercesi P, Lissoni A. Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care Med 1998;158:3-11.
  • 44) Gattinoni L, Caironi P, Cressoni M, Chiumello D, Ranieri VM, Quintel M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med 2006; 354:1775-86.
  • 45) Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138:62-8.
  • 46) Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:1565-70.
  • 47) Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280:159-65.
  • 48) Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348:683-93.
  • 49) Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-84.
  • 50) Philit F, Etienne-Mastroïanni B, Parrot A, Guérin C, Robert D, Cordier JF. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002; 166:1235-9.
  • 51) Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008;336:1006-9.
  • 52) Marik PE. Critical illness-related corticosteroid insufficiency. Chest 2009;135:181-93.
  • 53) Sakka SG, Klein M, Reinhart K, Meier-Hellmann A. Prognostic value of extravascular lung water in critically ill patients. Chest 2002;122:2080-6.
  • 54) Humphrey H, Hall J, Sznajder I, Silverstein M, Wood L. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest 1990;97:1176-80.
  • 55) Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 2005;33:1681-7.
  • 56) Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005;293:470-6.
  • 57) Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004;291:1603-9.
  • 58) Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005;353:2683-95.
  • 59) Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O�Brien J, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104:3878-85.
  • 60) Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008;178:618-23.
  • 61) Sakuma T, Okaniwa G, Nakada T, Nishimura T, Fujimura S, Matthay MA. Alveolar fluid clearance in the resected human lung. Am J Respir Crit Care Med 1994;150:305-10.
  • 62) Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002;346:1631-6.
  • 63) Perkins GD, McAuley DF, Thickett DR, Gao F. The betaagonist lung injury trial (BALTI): a randomized placebocontrolled clinical trial. Am J Respir Crit Care Med 2006; 173:281-7.
  • 64) Mikawa K, Akamatsu H, Maekawa N, Nishina K, Obara H, Niwa Y. Inhibitory effect of prostaglandin E1 on human neutrophil function. Prostaglandins Leukot Essent Fatty Acids 1994;51:287-91.
  • 65) Russell JA, Ronco JJ, Dodek PM. Physiologic effects and side effects of prostaglandin E1 in the adult respiratory distress syndrome. Chest 1990;97:684 92.
  • 66) Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care 1999;14:1-6.
  • 67) Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA 2000;283:1995-2002.
  • 68) Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-8.
  • 69) Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997;112:164-72.
  • 70) Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al. Comparison of two fluidmanagement strategies in acute lung injury. N Engl J Med 2006;354:2564-75.
  • 71) Santos C, Ferrer M, Roca J, Torres A, Hernández C, Rodriguez-Roisin R. Pulmonary gas exchange response to oxygen breathing in acute lung injury. Am J Respir Crit Care Med 2000;161:26-31.
  • 72) Suzuki S, Hotchkiss JR, Takahashi T, Olson D, Adams AB, Marini JJ. Effect of core body temperature on ventilatorinduced lung injury. Crit Care Med 2004;32:144-9.
  • 73) Gainnier M, Roch A, Forel JM, Thirion X, Arnal JM, Donati S, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 2004;32:113-9.
  • 74) Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409 17.
  • 75) Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22.
  • 76) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-8.
  • 77) Iglesias M, Martinez E, Badia JR, Macchiarini P. Extrapulmonary ventilation for unresponsive severe acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 2008;85:237-44.
  • 78) Hommel M, Deja M, von Dossow V, Diemel K, Heidenhain C, Spies C, et al. Bronchial fistulae in ARDS patients: management with an extracorporeal lung assist device. Eur Respir J 2008;32:1652-5.
  • 79) Zimmermann M, Philipp A, Schmid FX, Dorlac W, Arlt M, Bein T. From Baghdad to Germany: use of a new pumpless extracorporeal lung assist system in two severely injured US soldiers. ASAIO J 2007;53:e4-6.
Türk Göğüs Kalp Damar Cerrahisi Dergisi-Cover
  • ISSN: 1301-5680
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1991
  • Yayıncı: Bayçınar Tıbbi Yayıncılık
Sayıdaki Diğer Makaleler

Stentsiz biyolojik aort kapak kullanımının akustik konforu

Kaan KIRALİ, İlker MATARACI, Alper ERKİN, Murat Eyüp ÖKTEN, Özgür KOCAMAZ, Tanıl ÖZER

Effects of positioning and ventilation strategy on the parameters of respiratory mechanics and blood gases during video-assisted thoracoscopic esophagectomy

Ezel ERSEN, Ahmet DEMİRKAYA, Bilgi BACA, İsmail HAMZAOĞLU, Tayfun KARAHASANOĞLU, Ziya SALİHOĞLU, Şener DEMİROLUK

Akut solunum sıkıntısı sendromu

Turgut IŞITMANGİL, Erdoğan KUNTER

Açık kalp ameliyatı geçirmiş bireylerin evde bakım gereksinimlerinin belirlenmesinde bir model: Fonksiyonel sağlık örüntüleri

Meryem YILMAZ, E. Selda ÇİFÇİ

Sağ koroner arter ve sağ ventrikül ilişkili fistülün cerrahi tedavisi: Olgu sunumu

Burak TAMTEKİN, Ünal AYDIN, Cihat BAKAY, Kerem ORAL, Vedat AYTEKİN, Aşkın Ali KORKMAZ, Burak ONAN

Acute exacerbation in chronic kidney disease increases mortality after coronary artery bypass grafting

Ozan Onur BALKANAY, Deniz GÖKSEDEF, Zeki TALAS, Suat Nail ÖMEROĞLU, Gökhan İPEK, Nevzat Cem SAYILGAN

Açık kalp cerrahisi yapılan düşük ağırlıklı hastalarda risk sınıflandırmaları

Sait AŞLAMACI, Hakkı Tankut AKAY, Salih ÖZÇOBANOĞLU, Tolga TATAR, Süleyman ÖZKAN, Murat ÖZKAN, Bülent SARITAŞ

An unusual location of hydatid disease: An asymptomatic case with rib destruction

Metin AKGÜN, Erdal YEKELER

Ailesel hiperkolesterolemili genç hastada supravalvüler aortik stenoz ve koroner arter hastalığının cerrahi tedavisi

Kaan KIRALİ, İlker MATARACI, Rahmi ZEYBEK, Cüneyt KELEŞ, Murat Bülent RABUŞ

Sternum primer tüberkülozu: Olgu sunumu

Alper AVCI, Şevval EREN

Academic Researches Index - FooterLogo